European Journal of Clinical Pharmacology

, Volume 15, Issue 5, pp 349–355 | Cite as

Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. Pharmacokinetics after an oral dose

  • L. Viinikka
  • O. Ylikorkala
  • R. Vihko
  • H. P. Wijnand
  • M. Booij
  • F. van der Veen


The pharmacokinetics of a new synthetic progestagen, Org 2969 (13-ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-ol) and its presumed active metabolite, 3-keto-Org 2969, were studied in five healthy female volunteers. During the first part of the study (Phase I), four volunteers ingested as a single dose 50 µg (about 100 µCi) of [16-3H]-Org 2969 together with 50 µg of ethinyl oestradiol. During the second part (Phase II), ten days of pretreatment with non-readioactive Org 2969 and ethinyl oestradiol preceded dosing, which was similar to that in Phase I. The fifth volunteer ingested 2500 µg of Org 2969 as a single dose. The concentrations of Org 2969 and 3-keto-Org 2969 in serum were measured by specific radioimmunoassay, and by as radioactivity. The maximum serum level of Org 2969 of 0.2–0.3% of the dose/litre was obtained 0.8–1.3 h after administration, and it was followed by a mono-exponential decrease, the half-life being 1.3–1.5 hours. No difference in Org 2969 levels was seen between Phase I and Phase II studies. The maximum 3-keto-Org 2969 serum level in Phase I was 0.4–0.8% of the dose/litre, 1–3 h after administration. A two-compartment open body model adequately described the data. The half-life of elimination was 16 hours. There was a considerable change in the single dose kinetics between Phase I and Phase II in the case of 3-keto-Org 2969. In Phase II the maximum serum level was 2.0–3.4% of the dose/litre, and there was no significant change in half-life. The change was considered to be due to a decrease in the apparent volume of distribution as a result of an increased number of binding sites on sex hormone-binding globulin induced by ethinyl oestradiol during the pretreatment period, and/or to an increase in the fraction of Org 2969 metabolized to 3-keto-Org 2969. The two simultaneous processes contributed to the change in kinetics and to the production of a steady state level of 3-keto-Org 2969 which resulted in a steady state within the first 10 days of daily administration of Org 2969 and ethinyl oestradiol.

Key words

contraception progestational steroid radioimmunoassay 

The following codes and trivial names were used

Org 2969

13-ethyl-11-methylene-18, 19-dinor-17α-pregn-4-en-20-yn-17-ol

3-keto-Org 2969

13-ethyl-17-hydroxy-11-methylene-18, 19-dinor-17α-pregn-4-en-20-yn-3-one

ethinyl oestradiol







Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Hümpel, M., Wendt, H., Pommerenke, G., Weiss, Chr., Speck, U.: Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women. Contraception17, 207–220 (1978)Google Scholar
  2. Mazaheri, A., Fotherby, K., Chapman, J.: Metabolism of lynestrenol to norethisterone by liver homogenate. J. Endocrinol.47, 251–252 (1970)Google Scholar
  3. Murata, S.: Studies about the metabolism of estrane-progestins. Folia Endocrinol. Jpn.43, 1083–1096 (1967)Google Scholar
  4. Nilsson, S., Victor, A., Nygren, K.-G.: Plasma levels of d-norgestrel and sex hormone binding globulin during oral d-norgestrel medication immediately after delivery and legal abortion. Contraception15, 87–92 (1977)Google Scholar
  5. Raynaud, J.-P.: Metabolism of contraceptive steroids in man. Excerpta Medica International Congress Series No. 219, Hormonal Steroids, Proceedings of the Third International Congress, Hamburg, September 1970Google Scholar
  6. Skouby, S.: The influence on the pituitary-ovarian function, cervical mucus and vaginal cytology of a new progestational compound. Contraception14, 529–539 (1976)Google Scholar
  7. Smit, W., Booij, M.: Parameter estimation in chemical reaction kinetics using a hybrid computer. Proceedings of Chemdata Congress, Helsinki (1977), in pressGoogle Scholar
  8. Victor, A., Weiner, E., Johansson, E.D.B.: Relation between sex hormone binding globulin and d-norgestrel levels in plasma. Acta endocrinol.86, 430–436 (1977)Google Scholar
  9. Viinikka, L.: Radioimmunoassay of a new progestagen, Org 2969, and its metabolite. J. Steroid Biochem.9, 979–982 (1978)Google Scholar
  10. Viinikka, L., Hirvonen, E., Ylikorkala, O., Nummi, S., Virkkunen, P., Ranta, T., Alapiessa, U., Vihko, R.: Ovulation inhibition by a new low dose progestagen. Contraception16, 51–58 (1977)Google Scholar
  11. Viinikka, L., Ylikorkala, O., Nummi, S., Virkkunen, P., Ranta, T., Alapiessa, U., Vihko, R.: Biological effects of a new and potent progestagen. A clinical study. Acta endocrinol.83, 429–438 (1976)Google Scholar
  12. De Visser, J., de Jager, E., de Jongh, H.P., van der Vies, J., Zeelen, F.: Pharmacological profile of a new orally active progestational steroid: Org 2969. Acta endocrinol. Suppl.199, 405 (1975)Google Scholar

Copyright information

© Springer-Verlag 1979

Authors and Affiliations

  • L. Viinikka
    • 1
  • O. Ylikorkala
    • 2
  • R. Vihko
    • 1
  • H. P. Wijnand
    • 3
  • M. Booij
    • 4
  • F. van der Veen
    • 3
  1. 1.Department of Clinical ChemistryUniversity of OuluFinland
  2. 2.Department of Obstetrics and GynaecologyUniversity of OuluFinland
  3. 3.Organon Scientific Development GroupOrganon Int., OssThe Netherlands
  4. 4.AKZO-Research LaboratoriesAnalogue Computer SectionArnhemThe Netherlands

Personalised recommendations